BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1676 related articles for article (PubMed ID: 28784671)

  • 1. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
    Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
    Pfaller MA; Messer SA; Jones RN; Castanheira M
    J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
    Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.
    Rybak JM; Dickens CM; Parker JE; Caudle KE; Manigaba K; Whaley SG; Nishimoto AT; Luna-Tapia A; Roy S; Zhang Q; Barker KS; Palmer GE; Sutter TR; Homayouni R; Wiederhold NP; Kelly SL; Rogers PD
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
    Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common
    Lim HJ; Shin JH; Kim MN; Yong D; Byun SA; Choi MJ; Lee SY; Won EJ; Kee SJ; Kim SH; Shin MG
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Int J Antimicrob Agents; 2017 Sep; 50(3):352-358. PubMed ID: 28689871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APX001A
    Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing epidemiology of candidaemia in Australia.
    Chapman B; Slavin M; Marriott D; Halliday C; Kidd S; Arthur I; Bak N; Heath CH; Kennedy K; Morrissey CO; Sorrell TC; van Hal S; Keighley C; Goeman E; Underwood N; Hajkowicz K; Hofmeyr A; Leung M; Macesic N; Botes J; Blyth C; Cooley L; George CR; Kalukottege P; Kesson A; McMullan B; Baird R; Robson J; Korman TM; Pendle S; Weeks K; Liu E; Cheong E; Chen S;
    J Antimicrob Chemother; 2017 Apr; 72(4):1103-1108. PubMed ID: 28364558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.